Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationA variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.The Promises of Quantitative Proteomics in Precision MedicinePrediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simulation.Role of Hepatic Drug Transporters in Drug Development.
P2860
Q28088352-C8CD3D6E-78C1-4089-8A0C-18834B299178Q37421626-87FCF547-93CE-4A8E-BE11-A4C4FF887DA3Q37647264-D6C4A451-C660-4EC9-9FCB-19864C6AE0D8Q38233298-23835120-447E-4D59-A71D-24BF8BE84EC9Q38302225-2AE37E08-8895-4FF6-88C4-B348DFF01124Q40905288-3431E30A-F71A-4EEB-AB74-2391E737DD4EQ41651472-44DC9055-D046-4721-851B-3BDBF786CA31Q41759104-66478BDD-EBBE-48AA-B781-3239856F2623Q46675919-7FD3DD15-28D6-4E57-8F1D-73ABC03C5F33Q47305834-4ADBD41D-2E63-4842-8B75-7AB9D61255B3Q51659233-DA7BB09E-56C3-4662-91E9-0A1EC0107E1B
P2860
Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Reduced physiologically-based ...... of drug-drug interaction risk.
@ast
Reduced physiologically-based ...... of drug-drug interaction risk.
@en
type
label
Reduced physiologically-based ...... of drug-drug interaction risk.
@ast
Reduced physiologically-based ...... of drug-drug interaction risk.
@en
prefLabel
Reduced physiologically-based ...... of drug-drug interaction risk.
@ast
Reduced physiologically-based ...... of drug-drug interaction risk.
@en
P2093
P2860
P1476
Reduced physiologically-based ...... of drug-drug interaction risk
@en
P2093
Carolina Säll
J Brian Houston
Michael Gertz
Nikolaos Tsamandouras
P2860
P304
P356
10.1007/S11095-014-1333-3
P577
2014-03-13T00:00:00Z